Quest PharmaTech Inc

Research Quest PharmaTech Inc (QPT) on Bullrun: valuation model: 388.0% undervalued, market cap CAD 5.07M, P/E 1.0. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerQPT
• ExchangeV
• CountryCanada
• SectorHealthcare
• IndustryBiotechnology
• CurrencyCAD
• Valuation signal388.0% undervalued
• Market capCAD 5.07M
• P/E1.0
• Financial periodQ4 2025
• Net incomeCAD 1.08M
• Free cash flow-CAD 35.00K

Valuation Snapshot

Bullrun's latest valuation model marks Quest PharmaTech Inc as 388.0% undervalued; latest market cap is CAD 5.07M; P/E is 1.0.

About Quest PharmaTech Inc

Quest PharmaTech Inc., a pharmaceutical company, develops targeted cancer therapies in Canada. Its lead product is MAb AR9.6, a theranostic agent for cancer in preclinical development for pancreatic cancer. The company is headquartered in Edmonton, Canada.

Frequently asked questions

Is Quest PharmaTech Inc overvalued or undervalued?

Bullrun's valuation model currently marks Quest PharmaTech Inc as 388.0% undervalued.

What is Quest PharmaTech Inc's market cap?

Quest PharmaTech Inc's market capitalization is CAD 5.07M.

What is Quest PharmaTech Inc's P/E ratio?

Quest PharmaTech Inc's price-to-earnings (P/E) ratio is 1.0.

What does Quest PharmaTech Inc do?

Quest PharmaTech Inc., a pharmaceutical company, develops targeted cancer therapies in Canada. Its lead product is MAb AR9.6, a theranostic agent for cancer in preclinical development for pancreatic cancer. The company is headquartered in Edmonton, Canada.